SecBot SecBot
6-K ·Filed Mar 30, 2026

GSK

GSK plc
BULLISH
Impact 7/10
Horizonmonths Processed7mo ago SEC0001654954-26-002916
Notable filing: 6-K
Actionable Insight ▲ Bullish

Traders should monitor upcoming sales figures for Exdensur in China and potential uptake dynamics, as this approval opens a large new market. Consider positioning ahead of respiratory segment earnings disclosures. Watch for NMPA decision on Exdensur for CRSwNP, which is under review.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$54.23
T+0 close · Mar 30, 2026 · via day close
Latest settled
−4.32%
T+60 · $51.89
Vs SPY
−20.81%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 30 $54.23entry
  2. T+1 · 8mo ago +1.77%α −1.12% · $55.19
  3. T+5 · 7mo ago +2.97%α −1.33% · $55.84
  4. T+20 · 7mo ago +0.44%α −12.15% · $54.47
  5. T+60 · 5mo ago −4.32%α −20.81% · $51.89
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

GSK plc announced that China's National Medical Products Administration (NMPA) has approved Exdensur (depemokimab) for the treatment of severe asthma with an eosinophilic phenotype in patients aged 12 and older. The approval is based on SWIFT-1 and SWIFT-2 phase III trials showing significant reductions in asthma exacerbations, with 58% and 48% lower annualized exacerbation rates versus placebo, respectively.

Key Facts

  • Exdensur approved in China for severe asthma with eosinophilic phenotype in patients aged 12+
  • Approval based on SWIFT-1 and SWIFT-2 phase III trials demonstrating 58% and 48% reduction in annualized exacerbation rates versus placebo
  • Exdensur is the first and only ultra-long-acting biologic in China with twice-yearly dosing for this indication
  • More than 2 million people in China suffer from severe asthma
  • Exdensur already approved in the US, EU, UK, and Japan for severe asthma and/or CRSwNP

Financial Impact

Potential for meaningful revenue growth in a high-burden, underserved market; China represents a major commercial opportunity given 46M adults with asthma and limited biologic options

revenuepipeline_value

Risk Factors

  • Commercial execution risk in China including pricing, reimbursement, and market access
  • Competition from existing biologics despite Exdensur's twice-yearly dosing advantage
  • Forward-looking statements include caution about actual results differing due to risks and uncertainties

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-002916
Document: 0001654954-26-002916-index-headers.html0001654954-26-002916
Document: 0001654954-26-002916-index.html0001654954-26-002916
Document: 0001654954-26-002916.txt0001654954-26-002916

US Market Status

Market Closed · Opens Wed (11h 10m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 30, 2026